Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

In my view, such adjustments are totally acceptable, and I shared my reasons - although obviously not directly comparable - ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...

GET MORE AI-GENERATED SIGNALS: November 09, 2024, 09:42 am ET, BY Chris- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999.